Kamfarma Group

Kamfarma, founded in 1978, is a Swiss Pharmaceutical Company interested in bringing in new investors from Biopharma, active family controlled pharmaceutical businesses, Pharmaceutical Leading Investing Distributors and Leading FDA, EU, Anvisa API Manufacturers to mitigate risk and participate in the Development of specialty complex pharmaceutical products, first to file, through either novel API synthesis, challenging clinical end points or unmet medical needs. Our entrepreneurial style does not have a specific therapeutic focus or market demographic or segment, up to date the USA is the Core Territory before globalizing followed by Europe, Russia, MENA, Japan and rest of the World.

Companies of the Group

Key facts

Kamfarma and its affiliates have raised & invested $80 million dollars since 2013, $24 million for U.S. focused products and $56 million for the rest of the world. All products target additional territories during or after the first country of launch is complete.

Kamfarma through its above affiliates has partnered with key global talented individuals and firms to conduct development work in U.S. and E.U. regulated countries with the key players vested in the development and clinical outcomes of every product.

The companies follow a novel model based on active partnerships of interested parties in a collaborative contract venture structure. A typical agreement is organized around a minimum investment of the Marketing Partners including the API developer or manufacturer, the finished product CDMO and/or the clinical CRO.

API development

Kamfarma maintains a capability for the development of innovative new process, non infringing API routes of synthesis. Kamfarma deploys these skills to patent new processes and/or circumvent existing patents of interest. Pilot plant capabilities up to several kilograms, close relationships with multiple API firms, and a new API factory is in place.

Finished Dosage Form development

Kamfarma funds, through one of its affiliates, the Finished Dosage Form co-development exclusively for our Marketing Partners and for API Suppliers including solid oral dosage forms, capsules, sublingual, extended release and delayed release, topical gels, parenteral dosages forms, lyophilized, sterile fill, pre-filled syringes and autoinjector pens.

API factories

Kamfarma specialize also in the Project Management of constructing multipurpose active ingredients factories for API not available on the open market, with new no infringing process ROS including providing the route of synthesis of the latest technological products on the market as well the finished dosage form formulation for such products.

To date Kamfarma has completed a 15 ton/Year factory, already in operation.

Kamfarma already planned a 50 ton/Year factory expandable to 100 ton/Year.

Commercialization strategy

The first market for any product is based on the expressed needs of the investing marketing partners, after which all products are considered for expansion in other markets globally, where commercially feasible.

This strategy allows leveraging the investments to additional territories for optimal financial returns. All relationships are on a product by product basis.

Critically, all investors get priority repayment prior to any profit sharing of the product once it is launched in the territory.

They also obtain royalties in proportion to the investment in the product asset in their territories as well as in the territories that they do not operate, including participation in license fees.

How we define ourselves

• A team with entrepreneurial spirit composed of 20 qualified persons globally with long standing experience in their field.
• Disrupting, innovative management of complex generics while destroying the old concept of traditional licensing whereby the investing partners receives worldwide profit sharing, participating in the license fees also, including territories where they do not operate.
• To be able to invest in the right product is a beautiful thing.
• We are a fully integrated company due to the fact that the API Manufacturers, Marketing Partners and CRO are all investing in the product.
• Our responsbility is that the investors are satisfied to secure continuous flow of return over time.